Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 7/20 | 0.39 |
| ▸ | REN | P00797 | 3/20 | 0.39 |
| ▸ | PREP | P48147 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PEPD | P12955 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL474931 | 1.00 | POLB (0.41) | POLBL3MBTL1ACERENPREP | |
| SCHEMBL4936887 | 1.00 | POLB (0.41) | POLBL3MBTL1ACERENPREP | |
| SCHEMBL2983461 | 0.94 | POLB (0.35) | POLBL3MBTL1ACERENPREP | |
| SCHEMBL3517261 | 0.94 | POLB (0.35) | POLBL3MBTL1ACERENPREP | |
| SCHEMBL3515949 | 0.94 | POLB (0.35) | POLBL3MBTL1ACERENPREP | |
| SCHEMBL25177843 | 0.86 | — | — | |
| SCHEMBL7447275 | 0.86 | — | — | |
| SCHEMBL7445466 | 0.86 | — | — | |
| SCHEMBL27955116 | 0.85 | ACE (0.38) | ACE | |
| SCHEMBL499793 | 0.85 | POLB (0.44) | POLBL3MBTL1ACERENPREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115974842-A | Preparation method of pyrroltinib | 苏州宝圣医药科技有限公司 | 2023-04-18 | — | — | CN | claimed |
| CN-118946557-A | Heteroaryl derivatives and uses thereof | 株式会社沃若诺伊 | 2024-11-12 | — | — | CN | disclosed |
| CN-115697967-B | Sulfonylbenzamide derivative and conjugate thereof, preparation method and application thereof | 江苏恒瑞医药股份有限公司 | 2024-10-22 | — | — | CN | disclosed |
| US-20240197737-A1 | APPLICATION OF COMPOUND IN PREPARATION OF INHIBITORY DRUG TARGETING ERBB2 MUTANT | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2024-06-20 | — | — | US | disclosed |
| WO-2024120419-A1 | FUSED TETRACYCLIC COMPOUNDS AS KRAS G12D MODULATORS AND USES THEREOF | ZAI LAB (SHANGHAI) CO., LTD. (CN) | 2024-06-13 | — | — | WO | disclosed |
| US-12006289-B2 | Potassium channel inhibitors | SANIONA A/S (DK) | 2024-06-11 | — | — | US | disclosed |
| CN-113631538-B | Novel potassium channel inhibitors | 萨尼奥纳有限责任公司 | 2024-05-31 | — | — | CN | disclosed |
| EP-4373825-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | Suvalent Therapeutics, Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| CN-118103370-A | Fused tetracyclic quinazoline derivatives as ERBB2 inhibitors | 英莱汶公司 | 2024-05-28 | — | — | CN | disclosed |
| US-20240116921-A1 | LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN INC. | 2024-04-11 | — | — | US | disclosed |
| US-6413984-B1 | REACTING PYRROLIDINE OR PIPERIDINE ALDEHYDE WITH METAL QUINO-LINE; OPTIONAL DEHYDROXYLATION AND/OR AMINE SUBSTITUTION; MIGRAINES, VASOCONSTRICTION OF NASAL MUCOSA, GASTROINTESTINAL DISORDERS, VEINOUS INSUFFICIENCY | SANOFI-SYNTHELABO (FR) | 2002-07-02 | — | — | US | disclosed |
| EP-1198456-A2 | POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2002-04-24 | — | — | EP | disclosed |
| US-20020028836-A1 | Potassium channel openers | ABBVIE INC. | 2002-03-07 | — | — | US | disclosed |
| EP-1150969-A1 | ALPHA-AZACYCLOMETHYL QUINOLINE DERIVATIVES FOR TREATING URINARY INCONTINENCE | SANOFI-SYNTHELABO (FR) | 2001-11-07 | — | — | EP | disclosed |
| WO-2001009096-A2 | POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2001-02-08 | — | — | WO | disclosed |
| WO-2000046219-A1 | ALPHA-AZACYCLOMETHYL QUINOLINE DERIVATIVES FOR TREATING URINARY INCONTINENCE | SANOFI-SYNTHELABO (FR) | 2000-08-10 | — | — | WO | disclosed |
| WO-1998033793-A1 | α-AZACYCLOMETHYL BENZOTHIOPHENE AND α-AZACYCLOMETHYL BENZOFURANE DERIVATIVES, PREPARATION AND THERAPEUTIC APPLICATION | SANOFI-SYNTHELABO (FR) | 1998-08-06 | — | — | WO | disclosed |
| US-5128483-A | CNS Disorders | AMERICAN CYANAMID COMPANY (US) | 1992-07-07 | — | — | US | disclosed |
| US-5001142-A | Alzheimer's disease | AMERICAN CYANAMID COMPANY (US) | 1991-03-19 | — | — | US | disclosed |
| EP-0408879-A2 | 1-Substituted-2-(3-amino-1-propynyl)-pyrrolidine derivatives | AMERICAN CYANAMID COMPANY (US) | 1991-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028836-A1 | Potassium channel openers | KCNJ2, KCNJ11, KCNJ1 | POLB 3650/4885L3MBTL1 869/4885ACE 3807/4885 |
| US-20240116921-A1 | LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 | ERBB2, FGFR2, ERBB3 | POLB 1659/4885L3MBTL1 1234/4885ACE 2812/4885 |
| US-20240197737-A1 | APPLICATION OF COMPOUND IN PREPARATION OF INHIBITORY DRUG TARGETING ERBB2 MUTANT | ERBB2, EGFR, GRB2 | POLB 3048/4885L3MBTL1 2928/4885ACE 1713/4885 |
| US-12006289-B2 | Potassium channel inhibitors | KCNJ2, KCNN2, KCNN1 | POLB 4725/4885L3MBTL1 2354/4885ACE 1992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.